RxSight, Inc. to Present at the Stifel 2026 Virtual Ophthalmology Forum
Rhea-AI Summary
RxSight (NASDAQ: RXST) will participate in the Stifel 2026 Virtual Ophthalmology Forum. Company management is scheduled for a fireside chat on Tuesday, May 26, 2026, at 10:00 a.m. Pacific Time.
A live and archived webcast will be accessible via RxSight’s investor relations website.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – RXST
On the day this news was published, RXST gained 1.18%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
RXST gained 0.5% with modestly elevated volume while peers were mixed: DCTH and SENS down, BFLY, CBLL, and NPCE up. Momentum scanner shows PACB up and BFLY down, reinforcing a stock-specific move around this forum news rather than a broad ophthalmic devices rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 06 | Q1 2026 earnings | Negative | -14.4% | Soft Q1 revenue, wider net loss, reiterated full‑year guidance. |
| Apr 29 | Conference appearance | Positive | +3.8% | Participation in Bank of America healthcare conference fireside chat. |
| Apr 22 | Earnings date notice | Neutral | -2.7% | Announcement of Q1 2026 results reporting date and call details. |
| Apr 08 | Clinical milestone | Positive | -7.0% | Milestone of 300,000 Light Adjustable Lens implants and ASCRS presence. |
| Apr 02 | Conference participation | Positive | +5.7% | Needham virtual healthcare conference fireside chat and webcast access. |
Mixed reactions: earnings and milestone updates have sometimes sold off, while conference appearances have previously coincided with positive moves.
Over the last few months, RxSight reported weaker Q1 2026 results, with revenue down and losses wider, which was followed by a -14.45% move after earnings on May 6, 2026. Earlier, multiple conference and forum appearances on April 2 and April 29 were paired with positive price reactions. A major milestone on April 8 highlighting 300,000 Light Adjustable Lens implants, however, saw a negative move. Today’s Stifel virtual forum news fits the pattern of ongoing investor outreach events.
Market Pulse Summary
This announcement highlights RxSight’s continued participation in investor and industry events, with a fireside chat at the Stifel 2026 Virtual Ophthalmology Forum on May 26, 2026. Historically, similar conference appearances have sometimes aligned with constructive trading, while earnings and milestone news have produced mixed reactions. With shares at $6.00, well below the $16.74 52-week high and under the $8.68 200-day MA, investors may watch execution on growth, margins, and future updates alongside ongoing outreach.
AI-generated analysis. Not financial advice.
ALISO VIEJO, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., today announced plans to participate in the upcoming Stifel 2026 Virtual Ophthalmology Forum. Management is scheduled to participate in a fireside chat on Tuesday, May 26, 2026, at 10:00 a.m. Pacific Time. A live and archived webcast of the presentation will be available on the company’s investor relations website at https://investors.rxsight.com/.
About RxSight, Inc.
RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®/LAL+®, collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.
Investor Relations Contact:
Oliver Moravcevic
VP, Investor Relations
omoravcevic@rxsight.com
